Plasmodium falciparum blood-stage enzyme or protein targeted by artemisinin

The entry "Plasmodium falciparum blood-stage enzymes/proteins targeted by artemisinins/piperazine derivatives" is not a single molecular target but a collective group of proteins and enzymes from the malaria parasite Plasmodium falciparum that are known to be alkylated or otherwise inhibited by the antimalarial drug artemisinin and structurally diverse piperazine derivatives. Proteomic studies using chemical probes have identified over 100 covalently modified protein targets, including essential components of hemoglobin degradation (such as falcipain and plasmepsin proteases), glycolysis (e.g., lactate dehydrogenase), antioxidant defense (e.g., thioredoxin reductase), nucleic acid synthesis (e.g., dihydrofolate reductase-thymidylate synthase), and ion homeostasis (e.g., P-type ATPases such as PfATP4). This broad and multi-pathway targeting, activated by haem generated from haemoglobin digestion, underlies the exceptional potency and speed of action for artemisinin-based drugs. However, this entry is scientifically imprecise as it refers to a heterogeneous group of molecules rather than a single defined target, and should be replaced with more specific protein or enzyme names when used in structured databases or medicinal chemistry projects[1][2][3][4][5][6]. Key enzymes and proteins targeted (examples): - Plasmepsin II, Plasmepsin IX/X (aspartic proteases) - Falcipain family (cysteine proteases) - Lactate dehydrogenase (glycolysis) - Thioredoxin reductase (antioxidant defense) - Dihydrofolate reductase-thymidylate synthase (nucleotide synthesis) - P-type ATPase 4 (PfATP4) - Ribosomal proteins (protein synthesis) - Other enzymes in purine/pyrimidine metabolism and transporters[1][2][3][4][5][6][8]. Note: This entry is not sufficiently specific for use as a canonical target name in structured therapeutic or pharmacological datasets because it aggregates dozens of individual proteins and enzymes, each of which would normally be catalogued separately with their own properties, abbreviations, and pharmacology. For structured records, use the specific protein names (e.g., "Plasmepsin II", "Falcipain-2", "P-type ATPase 4") whenever possible.

Other names

Plasmodium falciparum blood-stage molecular targets of artemisininsPf blood-stage artemisinin targetsP. falciparum blood-stage drug targets

Activation by haem (or ferrous iron) released during hemoglobin digestion causes artemisinin to generate free radicals that alkylate and inactivate multiple parasite proteins/enzymes, disrupting essential metabolic pathways and leading to parasite death Piperazine derivatives have been shown to inhibit a range of parasite enzymes/proteins, often by binding active sites or inhibiting function, with some structural overlap in targeted pathways